TriSalus Life Sciences, Inc.
TLSI
$6.45
-$0.55-7.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.21M | 35.99M | 32.14M | 29.43M | 26.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.21M | 35.99M | 32.14M | 29.43M | 26.89M |
| Cost of Revenue | 6.42M | 5.52M | 4.63M | 4.10M | 3.47M |
| Gross Profit | 33.79M | 30.47M | 27.51M | 25.33M | 23.42M |
| SG&A Expenses | 51.43M | 48.80M | 45.94M | 45.55M | 43.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.20M | 68.71M | 65.71M | 67.34M | 69.75M |
| Operating Income | -33.00M | -32.72M | -33.56M | -37.91M | -42.86M |
| Income Before Tax | -39.58M | -31.17M | -27.21M | -30.04M | -55.57M |
| Income Tax Expenses | 6.00K | -2.00K | 8.00K | 6.00K | 8.00K |
| Earnings from Continuing Operations | -39.58 | -31.17 | -27.21 | -30.05 | -55.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.58M | -31.17M | -27.21M | -30.05M | -55.58M |
| EBIT | -33.00M | -32.72M | -33.56M | -37.91M | -42.86M |
| EBITDA | -32.30M | -32.01M | -32.82M | -37.16M | -42.12M |
| EPS Basic | -1.97 | -1.13 | -1.12 | -1.33 | -2.50 |
| Normalized Basic EPS | -0.82 | -0.74 | -1.04 | -1.08 | -1.53 |
| EPS Diluted | -1.97 | -1.13 | -1.12 | -1.33 | -2.50 |
| Normalized Diluted EPS | -0.82 | -0.74 | -1.04 | -1.08 | -1.53 |
| Average Basic Shares Outstanding | 132.13M | 115.57M | 106.48M | 101.28M | 96.96M |
| Average Diluted Shares Outstanding | 132.13M | 115.57M | 106.48M | 101.28M | 96.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |